Does the media prefer TNYA or ACRS?

In the previous week, Tenaya Therapeutics had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat Tenaya Therapeutics' score of 0.62 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, TNYA or CADL?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenaya Therapeutics N/A N/A -$90.60M -$0.47 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is TNYA or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -80.56% -65.21% Candel Therapeutics N/A -60.42% -41.33%

Does the media refer more to TNYA or CADL?

In the previous week, Candel Therapeutics had 6 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 9 mentions for Candel Therapeutics and 3 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.62 beat Candel Therapeutics' score of 0.20 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to TNYA or DNA?

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 1 mentions for Ginkgo Bioworks. Tenaya Therapeutics' average media sentiment score of 0.62 beat Ginkgo Bioworks' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AQST or TNYA?

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Aquestive Therapeutics and 3 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.62 beat Aquestive Therapeutics' score of 0.46 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tenaya Therapeutics (TNYA) Competitors

$0.74 +0.00 (+0.57%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$0.74 0.00 (-0.15%)

As of 06:46 AM Eastern

Compare

TNYA vs. ACRS, CADL, GYRE, DNA, and AQST

Should you buy Tenaya Therapeutics stock or one of its competitors? MarketBeat compares Tenaya Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tenaya Therapeutics include Aclaris Therapeutics (ACRS), Candel Therapeutics (CADL), Gyre Therapeutics (GYRE), Ginkgo Bioworks (DNA), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.

How does Tenaya Therapeutics compare to Aclaris Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Tenaya Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Tenaya Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Aclaris Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Aclaris Therapeutics	$7.83M	94.36	-$64.92M	-$0.56	N/A

Tenaya Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 441.20%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 117.39%. Given Tenaya Therapeutics' higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Tenaya Therapeutics had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat Tenaya Therapeutics' score of 0.62 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aclaris Therapeutics beats Tenaya Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Candel Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Candel Therapeutics had 6 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 9 mentions for Candel Therapeutics and 3 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.62 beat Candel Therapeutics' score of 0.20 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Candel Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Tenaya Therapeutics has a beta of 2.82, indicating that its share price is 182% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, indicating that its share price is 149% less volatile than the broader market.

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Candel Therapeutics' return on equity of -60.42% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Candel Therapeutics	N/A	-60.42%	-41.33%

Tenaya Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 441.20%. Candel Therapeutics has a consensus target price of $18.00, indicating a potential upside of 74.76%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Tenaya Therapeutics beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Gyre Therapeutics. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 1 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.87 beat Tenaya Therapeutics' score of 0.62 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
Tenaya Therapeutics	Positive

Gyre Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the broader market.

Gyre Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 157.97%. Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 441.20%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Gyre Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.30	$5.03M	-$0.09	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tenaya Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Summary

Tenaya Therapeutics beats Gyre Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Ginkgo Bioworks?

Tenaya Therapeutics (NASDAQ:TNYA) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 1 mentions for Ginkgo Bioworks. Tenaya Therapeutics' average media sentiment score of 0.62 beat Ginkgo Bioworks' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenaya Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Ginkgo Bioworks	$170.15M	3.81	-$312.76M	-$5.36	N/A

Tenaya Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 441.20%. Ginkgo Bioworks has a consensus price target of $8.50, indicating a potential downside of 14.46%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Tenaya Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

Tenaya Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Summary

Tenaya Therapeutics beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aquestive Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.82, indicating that its share price is 182% more volatile than the broader market.

Aquestive Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.72	-$83.78M	-$0.61	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

Tenaya Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Aquestive Therapeutics and 3 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.62 beat Aquestive Therapeutics' score of 0.46 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aquestive Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 104.33%. Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 441.20%. Given Tenaya Therapeutics' higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Aquestive Therapeutics and Tenaya Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Tenaya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNYA vs. The Competition

Export

Metric	Tenaya Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$159.47M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-1.57	20.90	27.24	24.87
Price / Sales	N/A	341.80	544.57	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	1.30	8.75	10.95	6.54
Net Income	-$90.60M	$23.81M	$3.57B	$336.70M
7 Day Performance	1.25%	3.60%	2.27%	2.81%
1 Month Performance	-15.05%	3.72%	1.35%	0.58%
1 Year Performance	22.57%	68.80%	36.67%	31.29%

Tenaya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNYA Tenaya Therapeutics	2.2916 of 5 stars	$0.74 +0.6%	$4.00 +441.2%	+20.9%	$159.47M	N/A	N/A	110	Gap Up
ACRS Aclaris Therapeutics	3.1559 of 5 stars	$4.84 +7.6%	$11.50 +137.6%	+272.5%	$628.49M	$7.83M	N/A	100
CADL Candel Therapeutics	2.7879 of 5 stars	$9.15 +10.1%	$18.00 +96.7%	+103.6%	$608.88M	N/A	N/A	60	News Coverage
GYRE Gyre Therapeutics	2.1565 of 5 stars	$6.13 -1.9%	$17.00 +177.3%	-10.3%	$606.43M	$116.59M	N/A	40
DNA Ginkgo Bioworks	0.2826 of 5 stars	$9.02 -1.7%	$8.50 -5.7%	-12.0%	$599.03M	$170.15M	N/A	640

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNYA) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. ACRS, CADL, GYRE, DNA, and AQST

How does Tenaya Therapeutics compare to Aclaris Therapeutics?

Summary

How does Tenaya Therapeutics compare to Candel Therapeutics?

Summary

How does Tenaya Therapeutics compare to Gyre Therapeutics?

Summary

How does Tenaya Therapeutics compare to Ginkgo Bioworks?

Summary

How does Tenaya Therapeutics compare to Aquestive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. ACRS, CADL, GYRE, DNA, and AQST

How does Tenaya Therapeutics compare to Aclaris Therapeutics?

Which has more risk and volatility, TNYA or ACRS?

Is TNYA or ACRS more profitable?

Which has better valuation & earnings, TNYA or ACRS?

Do analysts prefer TNYA or ACRS?

Do insiders & institutionals have more ownership in TNYA or ACRS?

Does the media prefer TNYA or ACRS?

Summary

How does Tenaya Therapeutics compare to Candel Therapeutics?

Does the media refer more to TNYA or CADL?

Which has stronger earnings and valuation, TNYA or CADL?

Which has more risk & volatility, TNYA or CADL?

Do insiders and institutionals have more ownership in TNYA or CADL?

Is TNYA or CADL more profitable?

Do analysts prefer TNYA or CADL?

Summary

How does Tenaya Therapeutics compare to Gyre Therapeutics?

Does the media favor GYRE or TNYA?

Which has more risk and volatility, GYRE or TNYA?

Do analysts prefer GYRE or TNYA?

Which has stronger earnings and valuation, GYRE or TNYA?

Do insiders & institutionals believe in GYRE or TNYA?

Is GYRE or TNYA more profitable?

Summary

How does Tenaya Therapeutics compare to Ginkgo Bioworks?

Do institutionals & insiders believe in TNYA or DNA?

Does the media refer more to TNYA or DNA?

Which has preferable valuation and earnings, TNYA or DNA?

Do analysts recommend TNYA or DNA?

Is TNYA or DNA more profitable?

Which has more risk and volatility, TNYA or DNA?

Summary

How does Tenaya Therapeutics compare to Aquestive Therapeutics?

Do institutionals and insiders have more ownership in AQST or TNYA?

Which has more volatility & risk, AQST or TNYA?

Which has preferable earnings and valuation, AQST or TNYA?

Is AQST or TNYA more profitable?

Does the media favor AQST or TNYA?

Do analysts recommend AQST or TNYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools